A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 6-10

  Chi, Dennis S ^a   Zivanovic, Oliver ^a   Palayekar, Meena J ^b   Eisenhauer, Eric L ^a   Abu Rustum, Nadeem R ^a   Sonoda, Yukio ^a   Levine, Douglas A ^a   Leitao, Mario M ^a   Brown, Carol L ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Advanced ovarian cancer; CA 125; Optimal cytoreduction

Indexed keywords

CA 125 ANTIGEN;

ABDOMINAL SURGERY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; PERITONEUM CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURGICAL APPROACH;

ADULT; CA-125 ANTIGEN; COHORT STUDIES; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 57649097026     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.010     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Murray T., Xu J., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
3. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55 (1994) 891-896
4. Le T., Krepart G.V., Lotocki R.J., and Heywood M.S. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 67 (1997) 208-214
5. Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., et al. Identification of prognostic factors in advanced ovarian epithelial carcinoma. Gynecol Oncol 82 (2001) 532-537
6. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
7. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77 (2000) 227-231
8. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 (2004) 650-654
9. Eisenhauer E.L., Abu-Rustum N., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
10. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma?. Gynecol Oncol 103 (2006) 559-564
11. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al., Gynecologic Oncology Group Study. et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 3621-3627
12. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
13. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
14. Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105 (2007) 211-217
15. Nelson B.E., Rosenfeld A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian cancer. J Clin Oncol 11 (1993) 166-172
16. Bristow R.E., Duska L., Lambrou N., Fishman E.K., O, Neill M.J., Trimble E.L., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
17. Gemer O., Segal S., and Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 80 (2001) 583-585
18. Saygili U., Guclu S., Uslu T., Erten O., Demir N., and Onvural A. Can serum CA-125 levels predict the optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol 86 (2002) 57-61
19. Cooper B.C., Sood A.K., Davis C.S., Ritchie J.M., Sorosky J.I., Anderson B., et al. Preoperative CA-125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100 (2002) 59-64
20. Memarzadeh S., Lee S.B., Berek J.S., and Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J of Gynecol Cancer 13 (2003) 120-124
21. Alcazar J.L., Miranda D., Unanue A., Novoa E., Alemán S., and Madariaga L. CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Intl J Gynecol Obstet 84 (2004) 173-174
22. Obediat B., Latimer J., and Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 57 (2004) 153-156
23. Rossi A.C., Di Vagno G., Cormio G., Cazzolla A., Stefanelli S., D, Elia E., et al. A retrospective study of preoperative CA-125 levels in 82 patients with ovarian cancer. Arch Gynecol Obstet 269 (2004) 263-265
24. Brockbank E.C., Ind T.E., Barton D.P., Shepherd J.H., Gore M.E., A, Hern R., et al. Preoperative predictors of suboptimal cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 14 (2004) 42-50
25. Eltabbakh G.H., Mount S.L., Beatty B., Simmons-Arnold L., Cooper K., and Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 95 (2004) 377-383
26. Everett E.N., Heuser C.C., Pastore L.M., Anderson W.A., Rice L.W., Irvin W.P., et al. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 193 (2005) 568-576
27. Gemer O., Lurian M., Gdalevich M., Kapustian V., Piura E., Schneider D., et al. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Sur Oncol 31 (2005) 1006-1010
28. Barlow T.S., Przybylski M., Schilder J.M., Moore D.H., and Look K.Y. The utility of presurgical CA 125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16 (2006) 496-500
29. Gilani M.M., Karimi Zarchi M., Ghaemmaghami F., Behtash N., Mousavi A.S., and Ansaripoor S. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 105 (2007) 780-783
30. Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC. Preoperative serum Ca-125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2007 [epub ahead of print].
31. Bristow R.E. Predicting "unresectable" ovarian cancer: taking aim at a moving target. Gynecol Oncol 100 (2006) 449-450
32. Axtell A., Lee M., Bristow R., Dowdy S.C., Cliby W.A., Raman S., et al. Computed tomography predictors of primary suboptimal cytoreduction in patients with advanced ovarian cancer: a multi-institutional reciprocal validation study. J Clin Oncol 25 (2007) 384-389
33. Salani R., Axtell A., Gerardi M., Holschneider C., and Bristow R.E. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 108 (2008) 271-275